454 related articles for article (PubMed ID: 34148351)
1. Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial.
Kline JA; Adler DH; Alanis N; Bledsoe JR; Courtney DM; d'Etienne JP; Diercks DB; Garrett JS; Jones AE; Mackenzie DC; Madsen T; Matuskowitz AJ; Mumma BE; Nordenholz KE; Pagenhardt J; Runyon MS; Stubblefield WB; Willoughby CB
Circ Cardiovasc Qual Outcomes; 2021 Jul; 14(7):e007600. PubMed ID: 34148351
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for a multicentre implementation trial of monotherapy anticoagulation to expedite home treatment of patients diagnosed with venous thromboembolism in the emergency department.
Kline J; Adler D; Alanis N; Bledsoe J; Courtney D; D'Etienne J; B Diercks D; Garrett J; Jones AE; MacKenzie D; Madsen T; Matuskowitz A; Mumma B; Nordenholz K; Pagenhardt J; Runyon M; Stubblefield W; Willoughby C
BMJ Open; 2020 Oct; 10(10):e038078. PubMed ID: 33004396
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
[TBL] [Abstract][Full Text] [Related]
6. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis.
Beam DM; Kahler ZP; Kline JA
Acad Emerg Med; 2015 Jul; 22(7):788-95. PubMed ID: 26113241
[TBL] [Abstract][Full Text] [Related]
7. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
Marshall A; Levine M; Hill C; Hale D; Thirlwall J; Wilkie V; French K; Kakkar A; Lokare A; Maraveyas A; Chapman O; Arif A; Petrou S; Maredza M; Hobbs R; Dunn JA; Young AM
J Thromb Haemost; 2020 Apr; 18(4):905-915. PubMed ID: 31995662
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.
Lu K; Liao QQ; Zhu KW; Yao Y; Cui XJ; Chen P; Bi Y; Zhong M; Zhang H; Tang JC; Yu Q; Yue JK; He H; Zhu ZF; Cai ZZ; Yang Z; Zhang W; Dong YT; Wei QM; He X
Adv Ther; 2024 Jan; 41(1):391-412. PubMed ID: 37987918
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
13. Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD-DPC.
Yamashita Y; Morimoto T; Yoshikawa Y; Yaku H; Sumita Y; Nakai M; Ono K; Kimura T
J Am Heart Assoc; 2020 Jan; 9(2):e014582. PubMed ID: 31918600
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
15. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
16. Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan - Results From Post-Marketing Surveillance (XASSENT).
Fukuda I; Hirayama A; Kawasugi K; Kobayashi T; Maeda H; Nakamura M; Yamada N; Tajima T; Tachiiri M; Okayama Y; Sunaya T; Hirano K; Hayasaki T
Circ J; 2023 Aug; 87(9):1175-1184. PubMed ID: 37245989
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies.
Liu ZY; Zhang HX; Ma LY; Mu GY; Xie QF; Zhou S; Wang ZN; Wang Z; Hu K; Xiang Q; Cui YM
BMC Cardiovasc Disord; 2022 Mar; 22(1):105. PubMed ID: 35287588
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis.
Lobastov K; Dubar E; Schastlivtsev I; Bargandzhiya A
J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101726. PubMed ID: 38008180
[TBL] [Abstract][Full Text] [Related]
20. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
